Results 1 to 10 of about 28,326 (256)

Circulating Tumor DNA (ctDNA) in Kidney Cancer: A Narrative Review

Société Internationale d’Urologie Journal, 2023
Circulating tumor DNA (ctDNA) has been investigated as a potential noninvasive biomarker for disease prognostication, monitoring, and treatment selection in various tumor types, including renal cell carcinoma (RCC). In this narrative review,
Wesley Yip, A. Ari Hakimi
doaj   +2 more sources

Molecular clustering on ctDNA improves the prognostic stratification of DLBCL patients compared to ctDNA levels [PDF]

Blood Advances
: Circulating tumor DNA (ctDNA) levels can help predict outcomes in diffuse large B-cell lymphoma (DLBCL), but its integration with DLBCL molecular clusters remains unexplored.
Kogila, Sreekar, Donatella Talotta, Chiara Cosentino, Nawar Maher, Zucchetto, Antonella, Renzo Luciano Boldorini, Bellia, Matteo, Gattei, Valter, Jana Nabki, Lodovico Terzi Di Bergamo, Luigi Petrucci, Di Rocco, Alice, Andorno, Annalisa, Alessio Bruscaggin, Vit, Filippo, Riccardo Dondolin, Moia, Riccardo, Pileri, Stefano A, Deambrogi, Clara, Mattia Schipani, Eleonora Secomandi, Ilaria Del Giudice, Dondolin, Riccardo, Irene Della Starza, Talotta, Donatella, Melle, Federica, Sreekar Kogila, Bashar Al Deeban, Almasri, Mohammad, Rasi, Silvia, Riccardo Moia, Stefania Cresta, Rossi, Davide, Terzi di Bergamo, Lodovico, Cosentino, Chiara, Vincenzo Canzonieri, Angela Lorenzi, Martelli, Maurizio, Bruna, Riccardo, Mouhssine, Samir, Valter Gattei, Clara Deambrogi, Bomben, Riccardo, Pietro Bulian, Schipani, Mattia, Petrucci, Luigi, Joseph Ghanej, Robin Foà, Bittolo, Tamara, Giulia Maria Rivolta, Riccardo Bruna, Giovanna Motta, Fabio Canal, Al Deeban, Bashar, Maurizio Martelli, Soscia, Roberta, Ghanej, Joseph, Antonella Zucchetto, Rivolta, Giulia Maria, Boldorini, Renzo Luciano, Cresta, Stefania, Secomandi, Eleonora, Matteo Bellia, Andorno, Annalisa Giovanna, Foà, Robin, Bulian, Pietro, Maher, Nawar, Abdurraouf Mokhtar Mahmoud, Samir Mouhssine, Mohammad Almasri, Silvia Rasi, Spina, Michele, Al Essa, Wael, Annalisa Andorno, Stefano Palazzolo, Riccardo Bomben, Nabki, Jana, Palazzolo, Stefano, Tamara Bittolo, Motta, Giovanna, Canal, Fabio, Salehi, Matin, Stefano Pileri, Della Starza, Irene, Gaidano, Gianluca, Del Giudice, Ilaria, Bruscaggin, Alessio, Mercalli, Francesca, Cividini, Luca, Mahmoud, Abdurraouf Mokhtar, Federica Melle, Filippo Vit, Davide Rossi, Leutner, Monica, Francesca Mercalli, Matin Salehi, Monica Leutner, Canzonieri, Vincenzo, Luca Cividini, Alice Di Rocco, Wael Al Essa, Lorenzi, Angela, Gianluca Gaidano, Deambrog, Clara, Michele Spina, Boldorini, Renzo, Roberta Soscia, Pileri, Stefano   +107 more
core   +7 more sources

The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST [PDF]

Clinical Cancer Research
Purpose: Changes in ctDNA levels during systemic treatment may predict treatment efficacy in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), but quantitative response criteria are not yet established.
Johansen, Malene W., Jakobsen, Anders K M, Lindgaard, Sidsel C., Jensen, Lars H, Johansen, Julia S, Rasmussen, Louise S, Jensen, Lars H., Spindler, Karen Lise G., Steiniche, Mette M., Hansen, Torben F., Steiniche, Mette M, Ladekarl, Morten; id_orcid, Jakobsen, Anders K.M., Chen, Inna M, Andersen, Rikke F., Johansen, Malene W, Ladekarl, Morten, Andersen, Rikke F, Rasmussen, Louise S., Chen, Inna M., Lindgaard, Sidsel C, Johansen, Julia S., Spindler, Karen-Lise G, Hansen, Torben F   +23 more
core   +9 more sources

ESR1 mutations in ER-positive breast cancer: from endocrine resistance to ctDNA-guided therapeutic interception [PDF]

Exploration of Targeted Anti-tumor Therapy
Endocrine resistance in estrogen receptor-positive (ER+) breast cancer has undergone a fundamental reconceptualization over the past decade. The discovery that activating mutations in the ESR1 gene encoding ERα emerge under aromatase inhibitor (AI ...
Thais Martinez, Samantha Wegner, Hisham F. Bahmad   +2 more
doaj   +2 more sources

Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis

Frontiers in Oncology, 2022
Cancer cells release nucleic acids, freely or associated with other structures such as vesicles into body fluids, including blood. Among these nucleic acids, circulating tumor DNA (ctDNA) has emerged as a minimally invasive biomarker for tumor molecular ...
Estela Sánchez-Herrero, Roberto Serna-Blasco, Atocha Romero   +2 more
exaly   +3 more sources

The Landscape of ctDNA in Appendiceal Adenocarcinoma

Clinical Cancer Research
Purpose: Appendiceal adenocarcinoma is a rare malignancy with distinct histopathologic subtypes and a natural history with metastasis primarily limited to the peritoneum.
Yousef, Abdelrahman, Zeineddine, Mohammad A, Taggart, Melissa, White, Michael G, Chowdhury, Saikat, Yousef, Mahmoud, Overman, Michael J, Helmink, Beth, Fallon, Eleanor A, Kee, Bryan, Drusbosky, Leylah M, Zeineddine, Fadl A, Fournier, Keith, Raghav, Kanwal, Uppal, Abhineet, Bhutiani, Neal, Gu, Yue, Newhook, Timothy, Shen, John Paul, Dansby, Julia, Kopetz, Scott, Dasari, Arvind, Hornstein, Nicholas   +22 more
core   +3 more sources

ctDNA in Pancreatic Adenocarcinoma: A Critical Appraisal

Current Oncology
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies due to late diagnosis and limited treatment options. Circulating tumor DNA (ctDNA) is a promising, minimally invasive biomarker that could improve the clinical outcomes of ...
William Sessions, Kyaw L. Aung, Yuhang Zhou, Sujata Ojha   +3 more
core   +3 more sources

ctDNA in the reading room: A guide for radiologists

European Journal of Radiology
•Liquid biopsy with ctDNA detection offers several advantages over traditional biopsy.•Clinical recommendations differ based on professional organization guidelines.•ctDNA strengthens medical imaging in monitoring treatment response and surveillance ...
Pearce, Hayes, Bialick, Steven, Pimentel, Agustin, Hosein, Peter J., Alessandrino, Francesco, Datta, Jashodeep, Chang, Yu-Cherng, Javitt, Marcia C.   +7 more
core   +3 more sources

Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA [PDF]

, 2023
Circulating tumour DNA (ctDNA) can be used to detect and profile residual tumour cells persisting after curative intent therapy1. The study of large patient cohorts incorporating longitudinal plasma sampling and extended follow-up is required to ...
Moore, David A, Stahl, Josh, Johnson, Laura, Daber, Robert D, Veeriah, Selvaraju, Martínez-Ruiz, Carlos, Stetson, Daniel, Hiley, Crispin T, Riley, Joan, Barrett, J Carl, Weiss, Jakob, Patel, Akshay J, Black, James RM, McGranahan, Nicholas, TRACERx, Consortium, Licon, Abel, Hackshaw, Allan, Chesh, Adrian, Gomes, Fabio, Frankell, Alexander M, Swanton, Charles, Shahpurwalla, Aamir, Chaunzwa, Tafadzwa L, Huebner, Ariana, Jamal-Hanjani, Mariam, Puttick, Clare, Litchfield, Kevin, Aerts, Hugo JWL, Lim, Emilia L, Bye, Hannah, Kortlever, Roderik M, Biswas, Dhruva, Karasaki, Takahiro, Abbosh, Christopher, Cook, Daniel E, Watkins, Thomas BK, Roberts, Paula, Kisistok, Judit, Odell, Aaron, Manzano, Elizabeth, Harrison, Thomas, Moreau, Mike, Godin-Heymann, Nadia, Bakir, Maise Al, Grigoriadis, Kristiana, Evan, Gerard I, Garnett, Aaron, Birkbak, Nicolai J, Pich, Oriol, Schroeder, Morgan R, Hodgson, Darren, Ward, Sophia, Shaw, Jacqui A, L'Hernault, Anne, Carey, Nicolas   +54 more
core   +9 more sources

Circulating tumor DNA (ctDNA) Detection via electrochemical Biosensing Tools

MANAS: Journal of Engineering
Cancer is characterized by the presence of mutated alleles in DNA, leading to the formation of tumors. A delayed diagnosis of this condition can result in fatal outcomes, making it a significant global cause of mortality.
Sonya Sahin, Nimet Yıldırım Tirgil
doaj   +2 more sources